<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244320</url>
  </required_header>
  <id_info>
    <org_study_id>527.38</org_study_id>
    <nct_id>NCT02244320</nct_id>
  </id_info>
  <brief_title>Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)</brief_title>
  <official_title>Observational Study in Patients With Functional BPH (Benign Prostatic Hyperplasia) Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the observational study were to investigate the switch from phytotherapy to
      ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of
      ≥ 8 points (International Prostate Symptom Score (IPSS))
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IPSS sum score</measure>
    <time_frame>Day 1, 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Quality-of-Life Index (QoL) rated on a 7-point scale</measure>
    <time_frame>Day 1, 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in sexual satisfaction rated on a 4-point scale</measure>
    <time_frame>Day 1, 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum urinary flow rate (ml/sec)</measure>
    <time_frame>Day 1, 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in residual urine volume (ml)</measure>
    <time_frame>Day 1, 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of the preceding phytotherapy on a 3-point scale</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of the therapy with ALNA® on a 3-point scale</measure>
    <time_frame>after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessment of the preceding phytotherapy by physician rated on 4-point scale</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessment of the therapy with ALNA® by physician rated on 4-point scale</measure>
    <time_frame>after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability assessment of the preceding phytotherapy by physician rated on 4-point scale</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability assessment of the therapy with ALNA® by physician rated on 4-point scale</measure>
    <time_frame>after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse drug reactions (ADR)</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4150</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>functional BPH</arm_group_label>
    <description>patients with functional BPH who switched from phytotherapy to ALNA®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <arm_group_label>functional BPH</arm_group_label>
    <other_name>ALNA®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with functional BPH symptoms recruited at urologist offices
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from BPH symptoms

          -  Preceding treatment with a phytotherapeutic for at least 4 weeks

          -  IPSS sum score ≥ 8 points prior to treatment start with ALNA®

          -  Indication for a switch to treatment with ALNA® for a minimum period of 2 months

        Exclusion Criteria:

          -  Patients fulfilling one of the general or specific contraindications listed in the
             ALNA® Summary of Product Characteristic, particularly patients with known
             hypersensitivities against tamsulosin hydrochloride or any other ingredient of the
             product, orthostatic dysregulation or severe liver insufficiency

          -  Patients receiving ALNA® within the 4 weeks prior to the start of the present
             observational study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

